CA2315232A1 - Integrin receptor antagonists - Google Patents

Integrin receptor antagonists Download PDF

Info

Publication number
CA2315232A1
CA2315232A1 CA002315232A CA2315232A CA2315232A1 CA 2315232 A1 CA2315232 A1 CA 2315232A1 CA 002315232 A CA002315232 A CA 002315232A CA 2315232 A CA2315232 A CA 2315232A CA 2315232 A1 CA2315232 A1 CA 2315232A1
Authority
CA
Canada
Prior art keywords
alkyl
aryl
group
aminocarbonyl
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002315232A
Other languages
English (en)
French (fr)
Inventor
Mark E. Duggan
James J. Perkins
Robert S. Meissner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9807384.4A external-priority patent/GB9807384D0/en
Priority claimed from GBGB9815803.3A external-priority patent/GB9815803D0/en
Application filed by Individual filed Critical Individual
Publication of CA2315232A1 publication Critical patent/CA2315232A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002315232A 1997-12-17 1998-12-14 Integrin receptor antagonists Abandoned CA2315232A1 (en)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US6990997P 1997-12-17 1997-12-17
US60/069,909 1997-12-17
GB9807384.4 1998-04-06
GBGB9807384.4A GB9807384D0 (en) 1998-04-06 1998-04-06 Vitronectin receptor antagonists
US8325098P 1998-04-27 1998-04-27
US60/083,250 1998-04-27
US9263098P 1998-07-13 1998-07-13
US60/092,630 1998-07-13
GBGB9815803.3A GB9815803D0 (en) 1998-07-21 1998-07-21 Vitronectin receptor antagonists
GB9815803.3 1998-07-21
PCT/US1998/026485 WO1999030713A1 (en) 1997-12-17 1998-12-14 Integrin receptor antagonists

Publications (1)

Publication Number Publication Date
CA2315232A1 true CA2315232A1 (en) 1999-06-24

Family

ID=27517454

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002315232A Abandoned CA2315232A1 (en) 1997-12-17 1998-12-14 Integrin receptor antagonists

Country Status (8)

Country Link
EP (1) EP1044001B1 (https=)
JP (1) JP2002508326A (https=)
AT (1) ATE299023T1 (https=)
AU (1) AU738452B2 (https=)
CA (1) CA2315232A1 (https=)
DE (1) DE69830806T2 (https=)
ES (1) ES2243015T3 (https=)
WO (1) WO1999030713A1 (https=)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000006169A1 (en) * 1998-07-29 2000-02-10 Merck & Co., Inc. Integrin receptor antagonists
AU748621B2 (en) * 1998-08-13 2002-06-06 Merck & Co., Inc. Integrin receptor antagonists
CA2360305A1 (en) 1999-02-09 2000-08-17 Bristol-Myers Squibb Company Lactam inhibitors of fxa and method
US7125883B1 (en) 1999-04-13 2006-10-24 Abbott Gmbh & Co. Kg Integrin receptor ligands
CN1589145A (zh) 1999-06-02 2005-03-02 麦克公司 αv整联蛋白受体拮抗剂
US6514964B1 (en) 1999-09-27 2003-02-04 Amgen Inc. Fused cycloheptane and fused azacycloheptane compounds and their methods of use
EP1229910A4 (en) 1999-10-04 2003-10-01 Merck & Co Inc integrin
US6849639B2 (en) 1999-12-14 2005-02-01 Amgen Inc. Integrin inhibitors and their methods of use
CA2397194C (en) 2000-01-20 2011-05-17 Mark E. Duggan Alpha v integrin receptor antagonists
US7119098B2 (en) 2000-06-15 2006-10-10 Pharmacia Corporation Heteroarylakanoic acids as intergrin receptor antagonists
US6511973B2 (en) 2000-08-02 2003-01-28 Bristol-Myers Squibb Co. Lactam inhibitors of FXa and method
WO2002022615A1 (en) 2000-09-14 2002-03-21 Merck & Co., Inc. Alpha v integrin receptor antagonists
CA2436130A1 (en) 2001-01-29 2002-08-08 Ortho-Mcneil Pharmaceutical, Inc. Substituted indoles and their use as integrin antagonists
JP4660067B2 (ja) 2001-04-24 2011-03-30 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗血管新生剤とＴＮＦαとを用いる組合せ療法
US6872730B2 (en) 2001-04-27 2005-03-29 3-Dimensional Pharmaceuticals, Inc. Substituted benzofurans and benzothiophenes, methods of making and methods of use as integrin antagonists
AU2003259891A1 (en) * 2002-08-16 2004-03-19 Janssen Pharmaceutica N.V. Piperidinyl compounds that selectively bind integrins
JP2006516144A (ja) 2002-12-20 2006-06-22 ファルマシア・コーポレーション インテグリン受容体アンタゴニスト誘導体としてのチアゾール化合物
UA87854C2 (en) 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
BRPI0706540A2 (pt) 2006-01-18 2011-03-29 Merck Patent Gmbh terapia especìfica usando ligantes de integrina para tratar cáncer
EP2441464B1 (en) 2007-01-18 2014-04-09 Merck Patent GmbH Integrin ligands for use in treating colon cancer
CN102448497A (zh) 2009-05-25 2012-05-09 默克专利有限公司 在癌症治疗中的西仑吉肽的持续给药
SI3050878T1 (sl) 2013-09-24 2022-01-31 Fujifilm Corporation Nova dušik-vsebujoča spojina ali njena sol ali kovinski kompleks le-te
ES2864079T3 (es) 2014-05-30 2021-10-13 Pfizer Derivados de carbonitrilo como moduladores selectivos del receptor de andrógenos
MX394210B (es) 2017-02-28 2025-03-04 Morphic Therapeutic Inc INHIBIDORES DE INTEGRINA AVß6.
MA52117A (fr) 2017-02-28 2022-04-06 Morphic Therapeutic Inc Inhibiteurs de l'intégrine (alpha-v) (bêta-6)
WO2020047208A1 (en) 2018-08-29 2020-03-05 Morphic Therapeutic, Inc. Inhibitors of (alpha-v)(beta-6) integrin
WO2020047239A1 (en) 2018-08-29 2020-03-05 Morphic Therapeutic, Inc. INHIBITING αV β6 INTEGRIN
SI3844162T1 (sl) 2018-08-29 2025-06-30 Morphic Therapeutic, Inc. Zaviralci integrina alfa v beta6
EP3873605B1 (en) 2018-10-30 2024-10-23 Gilead Sciences, Inc. Compounds for inhibition of alpha4beta7 integrin
ES3013256T3 (en) 2018-10-30 2025-04-11 Gilead Sciences Inc Imidazo[1,2-a]pyridine derivatives as alpha4beta7 integrin inhibitors for the treatment of inflammatory diseases
FI3873884T3 (fi) 2018-10-30 2025-02-24 Gilead Sciences Inc 3-(kinolin-8-yyli)-1,4-dihydropyrido[3,4-d]pyrimidiini-2,4-dionijohdannaisia alfa-4-beta-7-integriinin estäjinä tulehdussairauksien hoidossa
JP7189368B2 (ja) 2018-10-30 2022-12-13 ギリアード サイエンシーズ， インコーポレイテッド アルファ４ベータ７インテグリンの阻害のための化合物
WO2021030438A1 (en) 2019-08-14 2021-02-18 Gilead Sciences, Inc. Compounds for inhibition of alpha 4 beta 7 integrin
WO2023275715A1 (en) 2021-06-30 2023-01-05 Pfizer Inc. Metabolites of selective androgen receptor modulators

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4929618A (en) * 1988-03-25 1990-05-29 Ube Industries, Ltd. Piperdine and piperazine derivatives, and antihistaminic pharmaceutical compositions containing the same

Also Published As

Publication number Publication date
ES2243015T3 (es) 2005-11-16
WO1999030713A1 (en) 1999-06-24
JP2002508326A (ja) 2002-03-19
EP1044001A4 (en) 2003-01-29
DE69830806T2 (de) 2006-04-27
AU1912899A (en) 1999-07-05
DE69830806D1 (de) 2005-08-11
ATE299023T1 (de) 2005-07-15
EP1044001B1 (en) 2005-07-06
EP1044001A1 (en) 2000-10-18
AU738452B2 (en) 2001-09-20

Similar Documents

Publication Publication Date Title
EP1044001B1 (en) Integrin receptor antagonists
US6090944A (en) Alkanoic acid derivatives as αv integrin receptor antagonists
US6066648A (en) Integrin receptor antagonists
AU736026B2 (en) Integrin receptor antagonists
US6017926A (en) Integrin receptor antagonists
US6040311A (en) Integrin receptor antagonists
EP1040098B1 (en) Integrin receptor antagonists
US6784190B2 (en) Integrin receptor antagonists
EP1040111B1 (en) Integrin receptor antagonists
US6413955B1 (en) Integrin receptor antagonists
US6358970B1 (en) Integrin receptor antagonists
AU747503B2 (en) Benzazepine derivatives as alpha-V integrin receptor antagonists
US6211191B1 (en) Integrin receptor antagonists
US6916810B2 (en) αν integrin receptor antagonists

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued